Brigatinib: up next in our pipeline

An FDA breakthrough therapy under investigation in ALK+ NSCLC

LEARN MORE

A remarkable place doing remarkable work

We're looking for people who want to make a difference for cancer patients

OPEN POSITIONS

A unique, highly targeted approach to cancer

Our research & development program

LEARN MORE

NEWS & FEATURES

Latest News

2/16/17
Takeda Completes Acquisition of ARIAD Pharmaceuticals, Inc.
Read More
2/6/17
ARIAD Announces Submission of Marketing Authorization Application for Brigatinib to the European Medicines Agency
Read More

TWITTER FEED